Back to Agenda
Session 2: UK Disclosure Requirements Updates'
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure, AbbVie, United States
In recent months, the United Kingdom’s disclosure requirements post-Brexit have come into greater focus.
This session provides updates from the HRA on their disclosure requirements, and a sponsor perspective on using the latest guidance documents to meet the clinical trial disclosure requirements of the UK.
Speaker(s)
Naho Yamazaki, PHD
Deputy Director, Policy and Partnerships, Health Research Authority, United Kingdom
Expanding Disclosure Requirements From the HRA
Joyce Swart
Director, Clinical Trial Disclosure, Alcon Research, LLC, United States
Example of Interventional, Non-Interventional and Device Trials A Sponsor Walkthrough of UK Clinical Trial Disclosure Guidance
Have an account?